Skip to content

Effet of short peptide and whole protein type ONS on clinical outcome of GC patients after discharge and health economic evaluation

Effect of short peptide and whole protein type ONS on clinical outcome of GC patients after discharge and health economic evaluation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096633
Enrollment
Unknown
Registered
2025-01-27
Start date
2024-11-29
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Whole protein type ONS group:Whole-protein ONS was used for intervention, 50~150 g/d, sequential feeding, each bag was brewed evenly with 200mL of warm boiled water at 45~55°C, 1-3 times/d, sequential
Short peptide type ONS group:Short peptide ONS was used for intervention, 50~150 g/d, sequential feeding, each bag was brewed evenly with 200mL of warm boiled water at 45~55°C, 1-3 times/d, sequential

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18 ~75 years old; 2.The preoperative diagnosis has been made, and gastric cancer was diagnosed by pathological histology; 3.proposed total gastrectomy or distal gastrectomy; 4.Did not receive preoperative gastric cancer treatment (surgery, chemotherapy, radiotherapy, targeted therapy, etc); 5.A NRS 2002 score of 3 points before discharge; 6.To resume oral dietary intake before discharge; 7.Volunteer to join the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Functional-preserving gastrectomy (pyloric-preserving gastrectomy, segmental gastrectomy, local gastrectomy, endoscopic resection, and proximal gastrectomy); 2.With other cancers, severe heart disease, diabetes, and electrolyte disorders; 3.Severe liver and renal function abnormalities (ALT and AST=twice the upper limit of normal , Cr> 176 µ mol/L); 4.Galactosemia, abnormal amino acid metabolism or have known allergy to any component in the ONS formulation for study; 5.Postoperative gastrointestinal fistula, intestinal obstruction, and no residual bowel function; 6.During the pregnancy period or lactation period.

Design outcomes

Primary

MeasureTime frame
NR2002 score;PG-SGA score;SDSAT score;Laboratory indicators;Health economics evaluation indicators;

Secondary

MeasureTime frame
Incidence of complications after gastric cancer surgery;Gastrointestinal tolerance;Incidence of feeding intolerance;ONS compliance;

Countries

China

Contacts

Public ContactLi Shuhua

The First Affiliated Hospital of Nanchang University

412830372@qq.com+86 180 7009 4230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026